Contact us
Text Size
Large
Small
[This site uses JavaScript. Please do effectively and see the setting of JavaScript.]
About Takeda
Responsibility
Patient Assistance Program
Community Involvement
Culture of Compliance
R&D
Products
Newsroom
2010
2009
2008
2007
2006
2005
2004
2003
Press Center
Careers
Jobs
Submit Resume
Home
>
Newsroom
>
2004
2010
2009
2008
2007
2006
2005
2004
2003
Press Center
News and Press Releases
2004
October 29, 2004
Takeda Submits New Drug Application for Combination Type 2 Diabetes Medication, Actoplus MetTM (pioglitazone HCl and metformin HCl)
October 7, 2004
Takeda Announces Partnership with BioNumerik to Market Tavocept TM, Phase 3 Chemoprotective Agent, in North America
September 24, 2004
Takeda Submits New Drug Application for Ramelteon, an Investigational Sleep Drug
June 28, 2004
Landmark PROactive Trial Investigates Effect of ACTOS (pioglitazone HCl) on Cardiovascular Disease Progression
June 5, 2004
ACTOS® (pioglitazone HCl) Shows Sustained Efficacy Throughout Two-Year Period in Patients with Type 2 Diabetes
June 5, 2004
Studies Show ACTOS ® (pioglitazone HCl) Has Positive Effects on Various Components of Dyslipidemia
April 30, 2004
Combination Therapy with ACTOS® (pioglitazone HCl) Shown to Improve Components of Diabetic Dyslipidemia
January 6, 2004
Takeda Establishes Global Research and Development Center
Page Top